Aquestive Therapeutics AQST announced that the FDA has informed that no advisory committee meeting is required to discuss the new drug application (NDA) for AQST’s key product candidate, Anaphylm ...
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ...
The U.S. Food and Drug Administration (FDA) on Thursday informed Aquestive Therapeutics, Inc. (NASDAQ:AQST) that an advisory committee meeting is not required for Anaphylm (dibutepinephrine) ...
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST) one of those stocks right now? By taking a look at ...
The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate ...
Hosted on MSN
Why did AQST stock plunge 40% in pre-market today?
Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying ...
On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel. Aquestive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results